TTY Biopharm Co Ltd (4105) — Capital Reinvestment Ratio
TTY Biopharm Co Ltd (4105) has a Capital Reinvestment Ratio of 0.20x as of March 2026, meaning it reinvests 0% of its operating cash flow (NT$654.16 Million) in capital expenditures (NT$128.28 Million). Check TTY Biopharm Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
TTY Biopharm Co Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks TTY Biopharm Co Ltd's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see TTY Biopharm Co Ltd (4105) cash conversion ratio.
Annual Capital Reinvestment Ratio for TTY Biopharm Co Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for TTY Biopharm Co Ltd from 2017 to 2025. See 4105 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | NT$1.76 Billion | NT$150.83 Million | ▼ -14.0% |
| 2024 | 0.10x | NT$1.35 Billion | NT$134.29 Million | ▲ +8.5% |
| 2023 | 0.09x | NT$1.09 Billion | NT$99.58 Million | ▼ -16.3% |
| 2022 | 0.11x | NT$1.24 Billion | NT$135.50 Million | ▲ +85.8% |
| 2021 | 0.06x | NT$1.26 Billion | NT$74.15 Million | ▼ -82.9% |
| 2020 | 0.35x | NT$526.35 Million | NT$181.86 Million | ▲ +498.3% |
| 2019 | 0.06x | NT$1.21 Billion | NT$69.86 Million | ▼ -16.3% |
| 2018 | 0.07x | NT$1.07 Billion | NT$74.09 Million | ▼ -29.0% |
| 2017 | 0.10x | NT$996.52 Million | NT$96.79 Million | — |